Teva settles majority of US propofol HCV exposure lawsuits
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries is settling the vast majority of lawsuits arising out of claims relating to a product of Teva Parenteral Medicines and a hepatitis C outbreak in Southern Nevada. Just a handful of cases remain open. Patients claimed they developed hepatitis C virus (HCV) from vials of the anaesthesia drug propofol, which had become contaminated after being reused in colonoscopy procedures.